StockData
PMV Pharmaceuticals, Inc. logo

PMV Pharmaceuticals, Inc. (PMVP) stock

PMVPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.22+0.00 (0.00%)

Close on Nov 18, 2026Market cap $65.22MP/E –Yield –

PMV Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

PMV Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$79.66M. For fiscal 2025 it was -$86.21M. The highest annual figure on record is -$18.89M in fiscal 2018.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$86.21M–
FY2024Dec 31, 2024-$85.45M–
FY2023Dec 31, 2023-$80.13M–
FY2022Dec 31, 2022-$77.04M–
FY2021Dec 31, 2021-$58.29M–
FY2020Dec 31, 2020-$34.94M–
FY2019Dec 31, 2019-$26.64M–
FY2018Dec 31, 2018-$18.89M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$18.88M–
Q1 FY2026Mar 31, 2026-$19.02M–
Q4 FY2025Dec 31, 2025-$19.24M–
Q3 FY2025Sep 30, 2025-$22.52M–
Q2 FY2025Jun 30, 2025-$22.88M–
Q1 FY2025Mar 31, 2025-$21.56M–
Q4 FY2024Dec 31, 2024-$25.17M–
Q3 FY2024Sep 30, 2024-$21.89M–
Q2 FY2024Jun 30, 2024-$20.17M–
Q1 FY2024Mar 31, 2024-$18.22M–
Q4 FY2023Dec 31, 2023-$18.90M–
Q3 FY2023Sep 30, 2023-$19.63M–
Q2 FY2023Jun 30, 2023-$20.12M–
Q1 FY2023Mar 31, 2023-$21.48M–
Q4 FY2022Dec 31, 2022-$21.16M–
Q3 FY2022Sep 30, 2022-$19.38M–
Q2 FY2022Jun 30, 2022-$17.89M–
Q1 FY2022Mar 31, 2022-$18.62M–
Q4 FY2021Dec 31, 2021-$18.47M–
Q3 FY2021Sep 30, 2021-$15.10M–
Q2 FY2021Jun 30, 2021-$13.05M–
Q1 FY2021Mar 31, 2021-$11.67M–
Q4 FY2020Dec 31, 2020-$10.50M–
Q3 FY2020Sep 30, 2020-$8.70M–
Q2 FY2020Jun 30, 2020-$8.09M–
Q1 FY2020Mar 31, 2020-$7.65M–
Q4 FY2019Dec 31, 2019-$7.36M–
Q3 FY2019Sep 30, 2019-$6.44M–

More PMV Pharmaceuticals figures

See a number that looks wrong?